• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human GHR Polyclonal Antibody

The antibody against GHR was raised in Rabbit using the recombinant fusion protein containing a sequence corresponding to amino acids 26-260 of human GHR (NP_001229328.1) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, ELISA.

ADA-10169A

The antibody against GHR was raised in Rabbit using the recombinant fusion protein containing a sequence corresponding to amino acids 26-260 of human GHR (NP_001229328.1) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, ELISA.

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADA-10169A ClonalityPolyclonal
Host SpeciesRabbitTarget NameGHR
Target SynonymsGHBP; GHIP; GHRFormLiquid
Species ReactivityHuman, Mouse, RatIsotypeIgG
Storage Buffer50% Glycerol, PBS with 0.01% thimerosal, pH7.3.Purification MethodAffinity purification
Positive SamplesMouse heart, Mouse kidney, LO2, Rat liverApplicationELISA, WB

Immunogen Information


Immunogen DescriptionRecombinant fusion protein containing a sequence corresponding to amino acids 26-260 of human GHR (NP_001229328.1).Target SpeciesHuman
Uniprot IDP10912Immunogen Sequence
Background Information
  • Uniprot Id

    P10912

  • Target Species

    Human

  • Target Name

    GHR

  • Target Full Name

    Growth hormone receptor

  • Target Function

    Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway.; The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.; Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.

  • Target Involvement

    Laron syndrome (LARS); Growth hormone insensitivity, partial (GHIP)

  • Target Subcellular Location

    Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.

  • Target Protein Families

    Type I cytokine receptor family, Type 1 subfamily

  • Target Tissue Specificity

    Expressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. Isoform 1 expression in placenta is predominant in chorion and decidua. Isoform 4 is hig

  • Target Research Area

    Neuroscience

  • Target Synonyms

    GH receptor; GH-binding protein; GHBP; GHBP, included; GHR; GHR_HUMAN; Growth hormone binding protein; Growth hormone receptor; Growth hormone receptor precursor; Growth hormone-binding protein; Growth hormone-binding protein, included; Increased responsiveness to growth hormone, included; Serum binding protein; Serum-binding protein; Somatotropin receptor

  • Target Background

    This gene encodes a member of the type I cytokine receptor family, which is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to receptor dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature. In humans and rabbits, but not rodents, growth hormone binding protein (GHBP) is generated by proteolytic cleavage of the extracellular ligand-binding domain from the mature growth hormone receptor protein. Multiple alternatively spliced transcript variants have been found for this gene.

Inquire Rabbit anti-Human GHR Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification